

## Pharmaceutical Medicine ARCP Decision Aid 2021

This decision aid provides guidance on the requirement to be achieved for a satisfactory ARCP outcome at the end of each training year.

This document is available on FPM's website [www.fpm.org.uk](http://www.fpm.org.uk).

Evidence / requirement	Notes	Year 1 (ST3)	Year 2 (ST4)	Year 3 (ST5)	Year 4 (ST6)
<b>Pharmaceutical Medicine Educational Supervisor Report (PMESR)</b>	An indicative one per year to cover the training year since last ARCP (up to the date of the current ARCP)	Confirms meeting or exceeding expectations and no concerns	Confirms meeting or exceeding expectations and no concerns	Confirms meeting or exceeding expectations and no concerns	Confirms will meet all requirements needed to complete training
<b>Specialty capabilities in practice (CiPs)</b>	See grid below of levels expected for each year of training. Trainees must complete self-rating to facilitate discussion with ES. ES report will confirm entrustment level for each CiP	ES to confirm trainee is performing at or above the level expected for all CiPs	ES to confirm trainee is performing at or above the level expected for all CiPs	ES to confirm trainee is performing at or above the level expected for all CiPs	ES to confirm level 4 in all CiPs by end of training
<b>Generic capabilities in practice (CiPs)</b>	Mapped to the 'Generic professional capabilities framework' (GPC) and assessed using global ratings. See grid below of levels expected for each year of training. Trainees should record self-rating to facilitate discussion with ES. ES report will record rating for each generic CiP	ES to confirm trainee is performing at or above the level expected for all CiPs	ES to confirm trainee is performing at or above the level expected for all CiPs	ES to confirm trainee is performing at or above the level expected for all CiPs	ES to confirm level 4 in all CiPs by end of training
<b>PMAT</b>	An indicative 12 PMATs each year.	12	12	12	12

Evidence / requirement	Notes	Year 1 (ST3)	Year 2 (ST4)	Year 3 (ST5)	Year 4 (ST6)
<b>OAT</b>	An indicative four OATs each year.	4	4	4	4
<b>Quality Improvement Project Assessment (QIPAT)</b>	Project to be assessed with quality improvement project tool (QIPAT).	1	1	1	1
<b>Multi-Source Feedback (MSF)</b>	An indicative 12 respondents including senior pharmaceutical physicians, peers and a mixture of other staff (medical and non-medical). MSF report must be released by the ES and feedback discussed with the trainee before the ARCP. If significant concerns are raised then arrangements should be made for a repeat MSF.	1	1	1	1
<b>Patient Feedback (if applicable)</b>		1	1	1	1
<b>Diploma in Pharmaceutical Medicine (DPM) examination</b>	The trainee should attempt the DPM examination by at least year 2. The trainee and the ES should review the trainee's completion date regularly to ensure that plans to sit the exam are aligned with completing the training programme on time.	DPM	DPM	DPM	DPM (the trainee and the ES must review the completion date to ensure the trainee can sit and pass the exam on time).

## Levels to be achieved by the end of each training year and at critical progression points for the specialty and generic CiPs

<b>Level descriptors</b>	<b>Level 1</b> Entrusted to observe only	<b>Level 3</b> Entrusted to act with indirect supervision
	<b>Level 2</b> Entrusted to act with direct supervision	<b>Level 4</b> Entrusted to act unsupervised

Specialty CiP	ST3	ST4	ST5	ST6
Enables and supports patients' timely access to medicines appropriate for their clinical needs	1-2	2-3	3	4
Operates within ethical, regulatory and good practice frameworks	2	2-3	3	4
Participates in data generation, analysis and communication	2	2-3	3	4
Employs pharmacological and clinical data in the design, conduct, analysis and reporting of exploratory clinical trials for new medicines and devices	1-2	2-3	3	4
Conducts clinical research for the development of medical products	1-2	2-3	3	4
Engages in pharmacovigilance and risk-management systems to ensure patient safety and risk-minimisation	1-2	2-3	3	4
Provides up to date evaluations of the benefits and risks of medical products	2	2-3	3	4
Supports business decision-making and progression in medical product innovation and development	2	2-3	3	4

Critical progression point

Generic CiPs	ST3	ST4	ST5	ST6
Upholds professional standards and the duties of the GMC's 'Good Medical Practice' and the Faculty of Pharmaceutical Medicine's 'Good Pharmaceutical Medicine Practice'	4	-	-	-
Works competently within pharmaceutical organisational and management systems	3	4	-	-
Remains up to date with research and best practices in pharmaceutical medicine, employs reflective practice and undertakes continuing professional development	2-3	2-3	3	4
Applies the principles and practices of leadership and multi-disciplinary teamworking, teaching and developing others	2	2-3	3	4
Engages in quality improvement activities, ensuring that ethical, regulatory, and professional business standards are maintained	2	2-3	2-3	4
Keeps the safety of patients and the reliability of evidence at the forefront of decision-making in the design of development programmes for new and marketed medicines	2	2-3	2-3	4

Critical progression point